The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis

Schmitt, Jochen; Wozel, Gottfried

doi:10.1159/000083509

Cited by 394 publications

(313 citation statements)

References 58 publications

Supporting

Mentioning

290

Contrasting

Unclassified

Order By: Relevance

“…The ointment was applied once a day, for two hours. The intensity of psoriasis before and after two weeks of treatment was assessed using the PASI (Psoriasis Area and Severity Index) score according to Fredriksson and Pettersson [17], which is still widely use to estimate severity of the disease [18,19]. The erythema, infiltration and desquamation were separately estimated on the head, trunk, upper and lower limbs.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients

Myśliwiec

Flisiak

Baran

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Psoriasis is a chronic, recurrent, inflammatory disease. Recent investigations indicate an autoimmune pathogenesis of the disease. Apoptosis plays an important role in the regulation of immune mechanisms in many autoimmune diseases. Although CD40, CD40L, and Bcl-2 have already been studied in psoriatic skin lesions, little is known about their circulating forms. The aim of the present study was to evaluate the serum concentrations of Bcl-2, soluble CD40 and CD40L in psoriatic patients. The study was performed using ELISA kits in 39 psoriatic patients before treatment and after two weeks of topical ointment. Data was analyzed with respect to severity of psoriasis, duration of the disease, and coexisting psoriatic arthritis. Our results revealed that serum concentrations of soluble CD40 and CD40L before and after treatment were significantly higher (p < 0.01 and p < 0.001) in patients with psoriasis compared to the control group. Topical treatment of psoriatic lesions with dithranol ointment failed to decrease serum of CD40 and CD40L, which has not been described until now. There was no significant difference in serum Bcl-2 concentration between the compared groups. We did not find significant differences in serum concentrations of Bcl-2, CD40 or CD40L between patients with mild or severe psoriasis, nor any correlation between disease duration and the presence of psoriatic arthritis symptoms. Our data indicates upregulation of the CD40/CD40L system in psoriatic patients despite topical treatment and suggests their possible role in the pathogenesis of psoriasis.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients

Myśliwiec

Flisiak

Baran

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…Physical status was measured using the Health Assessment Questionnaire (HAQ) disability index [24]. Psoriasis severity was rated according to the Psoriasis area severity index (PASI) in PsA patients [25]. PASI combines the assessment of the severity of lesions and the affected area into a single score in the range from 0 (no disease) to 72 (maximal severity).…”

Section: Clinical Variablesmentioning

confidence: 99%

Which clinical variables have the most significant correlation with quality of life evaluated by SF-36 survey in Croatian cohort of patient with ankylosing spondylitis and psoriatic arthritis?

Jajić¹,

Rajnpreht²,

Kovačić

et al. 2011

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…Severity of psoriasis is evaluated by the Psoriasis Area and Severity Index (PASI, 3 Ref. 13), which in case of treatment with Alefacept, improves rather late during successful therapy. In a recent study, 55% of Alefacept-treated patients showed a remission of Ն50% of the psoriasis symptoms.…”

mentioning

confidence: 99%

Expression of Tolerance Associated Gene-1, a Mitochondrial Protein Inhibiting T Cell Activation, Can Be Used to Predict Response to Immune Modulating Therapies

Keeren

Friedrich

Gebuhr

et al. 2009

The Journal of Immunology

View full text Add to dashboard Cite

Immune modulating therapies gain increasing importance in treatment of patients with autoimmune diseases such as psoriasis. None of the currently applied biologics achieves significant clinical improvement in all treated patients. Because the therapy with biologics is cost intensive and sometimes associated with side effects, noninvasive diagnostic tools for early prediction of responders are of major interest. We studied the effects of Alefacept (LFA3Ig), an approved drug for treatment of psoriasis, on leukocytes in vitro and in vivo to identify gene markers predictive for treatment response and to further investigate its molecular mechanisms of action. In an open-label study, 20 psoriasis patients were treated weekly with 15 mg Alefacept over 12 wk. We demonstrate that transcription of the tolerance-associated gene (TOAG-1) is significantly up-regulated whereas receptor for hyaluronic acid mediated migration (RHAMM) transcription is down-regulated in PBMCs of responding patients before clinical improvement. TOAG-1 is exclusively localized within mitochondria. Overexpression of TOAG-1 in murine T cells leads to increased susceptibility to apoptosis. Addition of Alefacept to stimulated human T cells in vitro resulted in reduced frequencies of activated CD137+ cells, increased TOAG-1 but reduced RHAMM expression. This was accompanied by reduced proliferation and enhanced apoptosis. Inhibition of proliferation was dependent on enhanced PDL1 expression of APCs. Thus, peripheral changes of TOAG-1 and RHAMM expression can be used to predict clinical response to Alefacept treatment in psoriasis patients. In the presence of APCs Alefacept can inhibit T cell activation and survival by increasing expression of TOAG-1 on T cells and PDL1 on APCs.

show abstract

The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis

Cited by 394 publications

References 58 publications

Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients

Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients

Which clinical variables have the most significant correlation with quality of life evaluated by SF-36 survey in Croatian cohort of patient with ankylosing spondylitis and psoriatic arthritis?

Expression of Tolerance Associated Gene-1, a Mitochondrial Protein Inhibiting T Cell Activation, Can Be Used to Predict Response to Immune Modulating Therapies

Contact Info

Product

Resources

About